ArticleLeukemia2022

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.

Saurabh Zanwar et al.PubMed ↗Publisher ↗

No numbers read from the abstract.